Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NU201
- Development stage
- Unknown
- Lead developer
- Nuclidium
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
NU201 is a copper-based radiopharmaceutical developed by Nuclidium, designed to target the somatostatin receptor subtype-2 (SSTR2). It utilizes a theranostic approach, employing Copper-61 (61Cu) for diagnostic imaging and Copper-67 (67Cu) for targeted radionuclide therapy. As an SSTR2 antagonist, NU201 is designed to provide superior binding and tumor retention compared to traditional agonist-based radiopharmaceuticals. It is currently being evaluated in Phase 1 clinical trials for SSTR2-positive tumors, including metastatic breast cancer (mBC) and gastroenteropancreatic and bronchopulmonary neuroendocrine tumors (GEP & BP-NETs). The drug is part of Nuclidium's CuTrace™ platform, which focuses on the matched pair of copper isotopes for precision oncology.
- Other names
- 61Cu-SSTR2-antagonist67Cu-SSTR2-antagonist61Cu-NU20167Cu-NU201SSTR2-antagonistSSTR-2-antagonistSSTR 2-antagonist
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on NU201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NU201.